-
Targeting RET alterations in non-small cell lung cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-03-16 Go Nishikawa, Mark A. Klein
Rearranged during transfection (RET) alterations, which lead to aberrant activation of the proto-oncogene, have been identified in various cancers. In non-small cell lung cancer (NSCLC), mutations often manifest as fusion genes and are observed in 1–2 % of patients with NSCLC. In recent years, selective RET inhibitors such as selpercatinib and pralsetinib, approved by the Food and Drug Administration
-
Development and validation of nomogram models for predicting postoperative prognosis of early-stage laryngeal squamous cell carcinoma Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-03-15 Xu Juan, Huang Jiali, Liu Ziqi, Zhang Liqing, Zhou Han
We aimed to investigate the postoperative prognosis in patients with early-stage laryngeal squamous cell carcinoma (LSCC) in association with the preoperative blood markers and clinicopathological characteristics and to develop nomograms for individual risk prediction. The clinical data of 353 patients with confirmed early-stage LSCC between 2009 and 2018 were retrospectively retrieved from the First
-
Familial and Social Implications of Breast and Gynaecological cancer in Kerala, India Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-03-14 Lorane Scaria, Saju Madavanakadu Devassy, Lynette Joubert
Due to the paucity of reliable data to determine the components of family-based comprehensive care for cancer in India, we explored the familial implications of gynaecological and breast cancer diagnosis and treatment through a mixed-method study. The mixed method study included 130 women aged above 18 with a confirmed diagnosis of gynaecological or breast cancer recruited from three selected tertiary
-
Enhancing skin lesion classification with advanced deep learning ensemble models: a path towards accurate medical diagnostics Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-03-13 Kavitha Munuswamy Selvaraj, Sumathy Gnanagurusubbiah, Reena Roy Roby Roy, Jasmine Hephzipah John peter, Sarala Balu
Skin cancer, including the highly lethal malignant melanoma, poses a significant global health challenge with a rising incidence rate. Early detection plays a pivotal role in improving survival rates. This study aims to develop an advanced deep learning-based approach for accurate skin lesion classification, addressing challenges such as limited data availability, class imbalance, and noise. Modern
-
MET alterations in advanced non-small cell lung cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-03-13 Gabriel Cavalcante Lima Chagas, Amanda Ribeiro Rangel, Badi El Osta
Precision medicine has helped identify several tumor molecular aberrations to be treated with targeted therapies. These therapies showed substantial improvement in efficacy without excessive toxicity in patients with specific oncogenic drivers with advanced cancers. In metastatic lung cancers, the implementation of broad platforms for molecular tumor sequencing has helped oncology providers identify
-
Prognostic value of the peripheral blood lymphocyte/monocyte ratio combined with 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-02-15 Wenke Wu, Lidong Zhao, Ying Wang, Peng Chen, Xiaoshuai Yuan, Lei Miao, Yuanxin Zhu, Jianping Mao, Zhimei Cai, Yajun Ji, Lei Wang, Tao Jia
To explore the prognostic value of the peripheral blood lymphocyte/monocyte ratio (LMR) combined with F-FDG PET/CT for diffuse large B-cell lymphoma (DLBCL). The clinical data of 203 patients with primary DLBCL who were hospitalized to the First People's Hospital of Lianyungang between January 2017 and December 2022 were retrospectively analyzed. Before and after three courses of treatment, PET/CT
-
Targeting MEK in non-small cell lung cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-02-09 Matthew S. Lara, Collin M. Blakely, Jonathan W. Riess
The mitogen-activated protein kinase (MAPK or MEK) pathway modulates tumor cell survival and proliferation in non-small cell lung cancer (NSCLC). Unlike RAS or EGFR, activating mutations in MEK are exceedingly rare in NSCLC. Instead, enhanced activation of the MEK pathway is often linked to increased signaling by upstream oncogenic driver mutations. Thus far, MEK inhibitor monotherapy has shown little
-
The role of coenzyme Q10 as a preventive and therapeutic agent for the treatment of cancers Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-02-07 Ghazal Ghasempour Dabaghi, Mehrdad Rabiee Rad, Mahtab Mohammad-Zamani, Atieh Karimi Shervedani, Farnaz Bahrami-Samani, Kiyan Heshmat-Ghahdarijani
Currently, several options are available for the prevention and treatment of cancers; however, many limitations remain with these approaches. Recently, antioxidants have become important preventive and therapeutic alternatives with few adverse events and minimum cost. Coenzyme Q10 (CoQ10) is a naturally occurring component that performs an anticancer function by reducing oxidative stress. CoQ10 supplementation
-
Current management of uncommon EGFR mutations in non-small cell lung cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-02-03 Jonathan Q. Trinh, Omar Abughanimeh
Epidermal growth factor receptor (EGFR) mutations are frequently implicated in non-small cell lung cancer (NSCLC). Though these typically involve exon 19 in-frame deletions or L858R mutations in exon 21, uncommon EGFR mutations comprise 10-15 % of all EGFR mutations. These most frequently include G719X mutations in exon 18, L861Q mutations in exon 21, S768I mutations in exon 20, and in-frame insertions
-
Illuminating the breast cancer survival rates among Southeast Asian women: A systematic review and meta-analysis spanning four decades Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-02-02 Duc Tran Quang, Thanh Luong Thi, Khanh Nguyen Di, Chi Vu Thi Quynh, Huyen Nguyen Thi Hoa, Quang Phan Ngoc
In Southeast Asia, breast cancer is the most prevalent cancer among women and ranks as the second leading cause of cancer-related deaths. This systematic review and meta-analysis, encompassing 27 observational cohort studies with a minimum one-year follow-up period, aimed to examine temporal trends in breast cancer survival rates. Among the subset of five out of eleven Southeast Asian nations with
-
Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-01-27 Megan Rutherford, Margaret Wheless, Katharine Thomas, Robert A. Ramirez
Pulmonary neuroendocrine tumors represent a spectrum of disease ranging from typical carcinoid tumors to small cell lung cancers. The incidence of low-grade pulmonary NETs has been increasing, leading to improved awareness and the need for more treatment options for this rare cancer. Somatostatin analogs continue to be the backbone of therapy and may be followed or accompanied by targeted therapy,
-
Association between time from diagnosis to treatment and survival of patients with nasopharyngeal carcinoma: A population-based cohort study Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-01-11 Xiaoyuan Wei, Siting Yu, Jun Wang, Zhongzheng Xiang, Lei Liu, Yu Min
Treatment delays have frequently been observed in cancer patients. Whether the treatment delays would impair the survival of patients with nasopharyngeal carcinoma (NPC) is still unclear. The data were derived from the Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015. Patients were divided into groups of timely treatment (<1 month), intermediate delay (1 and 2 months)
-
Blood-based multi-cancer detection: A state-of-the-art update Curr. Probl. Cancer (IF 2.6) Pub Date : 2024-01-05 Maria Farooq, Elyse Leevan, Jibran Ahmed, Brian Ko, Sarah Shin, Andre De Souza, Naoko Takebe
The early detection of cancer is a key goal of the National Cancer Plan formally released by the National Institutes of Health's (NIH) National Cancer Institute (NCI) in April 2023. To support this effort, many laboratories and vendors are developing multi-cancer detection (MCD) assays that interrogate blood and other bodily fluids for cancer-related biomarkers, most commonly circulating tumor DNA
-
A novel model to predict the risk of hematological toxicity in lung adenocarcinoma patients with pemetrexed plus platinum chemotherapy based on real-world data Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-12-15 Wei-Jing Gong, Peng Cao, Yi-Fei Huang, Ya-Ni Liu, Yu Yang, Rui Zhang, Qiang Li, San-Lan Wu, Yu Zhang
Pemetrexed plus platinum chemotherapy is the first-line treatment option for lung adenocarcinoma. However, hematological toxicity is major dose-limiting and even life-threatening. The ability to anticipate hematological toxicity is of great value for identifying potential chemotherapy beneficiaries with minimal toxicity and optimizing treatment. The study aimed to develop and validate a prediction
-
Controversies in the treatment of early-stage oral squamous cell carcinoma Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-12-13 Leonardo Ferrari, Paolo Cariati, Imanol Zubiate, Ángel Martínez-Sahuquillo Rico, Susana Arroyo Rodriguez, Rosa Maria Pulgar Encinas, Silvano Ferrari, Ildefonso Martínez Lara
The treatment of early-stage oral squamous cell carcinoma (OSCC) is still a controversial issue. Thanks to the 8 edition of TNM by AJCC there is a better distinction between the stages of OSCC. However, Stages I and II still share the same treatment protocol, even if the prognosis is radically different. A retrospective study has been conducted including 70 previously untreated patients with Stage
-
The diagnostic value of serum lncRNA CATG00000112921.1 as a marker of multiple myeloma Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-12-09 Jing Gao, Jing Qu, Bin Xiao, Qiyuan Huang, Chuiyu Zhu, Zichang Dai, Kunhe Wu, Linhai Li, Tao Zeng
Multiple myeloma (MM) is a malignant plasma cell disease. At present, numerous studies have shown that lncRNA plays a very important role in the occurrence, development and even drug resistance of multiple myeloma. It may become a potential diagnostic and prognostic marker of multiple myeloma and provide new ideas for targeted therapy. Based on the above research background, this study used gene chip
-
Chemoradiotherapy treatment with gemcitabine improves renal function in locally advanced cervical cancer patients with renal dysfunction Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-11-20 Silvia Alarcón-Barrios, Julissa Luvián-Morales, Denisse Castro-Eguiluz, Merari Delgadillo-González, Brenda Olivia Lezcano-Velázquez, Eder Alexandro Arango-Bravo, Laura Flores-Cisneros, Sebastián Aguiar Rosas, Lucely Cetina-Pérez
Cervical cancer (CC) in Mexico is diagnosed mainly in locally advanced (LACC) and advanced (ACC) stages, where ureteral obstruction is more frequent. The standard treatment for this population is concurrent chemoradiotherapy (CCRT) with cisplatin, which is nephrotoxic and could lead to further deterioration of renal function in LACC patients with renal function decline. We aimed to evaluate the effect
-
Effects of nutritional indices and inflammatory parameters on patients received immunotherapy for non-small cell lung cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-11-20 Hui-Ping Ding, Yi-Qun Ling, Wei Chen, Qin Ding, Liu-Qing Xu, Yan Wu, Qiong Wang, Tian-Hao Ni, Bing-Qin He
This research explored the relationship between a patient's nutritional state and inflammatory markers and the prognosis of their non-small cell lung cancer (NSCLC) treatment while receiving a combination of chemotherapy and immunotherapy. This retrospective and single-center analysis included NSCLC patients who received a combination of chemotherapy and immunotherapy at the Department of Oncology
-
Using machine learning algorithms to predict the prognosis of advanced nasopharyngeal carcinoma after intensity-modulated radiotherapy Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-11-16 Dan Hu, Ying Wang, Genxin Ji, Yu Liu
The prognosis of advanced nasopharyngeal carcinoma (NPC) patients after intensity-modulated radiotherapy (IMRT) has not been well studied. We aimed to construct prognostic models for advanced NPC patients with stage III-IV after their first treatment with IMRT by using machine learning algorithms and to identify the most important predictors. A total of 427 patients treated in Meizhou People's Hospital
-
Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-11-10 Leena Gupta, Pratibha Suku, Aishwarya Dash, Parveen Bose, Praveen Sharma, Nabhajit Mallik, Sreejesh Sreedharanunni, Neelam Varma, Aditya Jandial, Pankaj Malhotra, Man Updesh Singh Sachdeva
Circulating plasma cells (CPCs) are frequently noted in variable frequencies in the entire spectrum of plasma cells neoplasms. With advent of high sensitivity multi-parametric flow cytometry, it is not only possible to detect CPCs present in very low numbers, but also to categorise them into circulating tumor plasma cells (CTPCs) and circulating normal plasma cells (CNPCs), based on their marker-profile
-
Changing trends in disease burden of lung cancer in China from 1990-2019 and following 15-year prediction Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-11-04 Di Zhao, Jinzhi Lu, Wen Zeng, Cong Zhang, Yonghao You
As lung cancer becomes a primary source of death in China, investigation on incidence rate, death rate, and disability-adjusted life years (DALYs) is of great significance to optimize prevention measures and allocation of healthcare resources. We utilized data from the Global Burden of Disease (GBD) database to evaluate the incidence rate, death rate, and DALYs of lung cancer in China from 1990 to
-
Frailty and Preoperative Palliative Care in Surgical Oncology Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-10-16 Zoe Tao, Elizabeth Hays, Gabrielle Meyers, Timothy Siegel
In this paper, we discuss surgical palliative care for patients with cancer through the lens of frailty and the preoperative context. Historically, palliative care principles such as complex symptom management, high-risk decision-making and communication have played an important role in preoperative discussions of oncologic surgery for both palliative and curative intent. There is increasing motivation
-
Barriers, blocks, and barricades: Disparities to access of palliative care in cancer care Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-10-17 Sonia Malhotra, Michelle Christopher, Rajasree Pia Chowdry, Brenna Mossman, Amanda Cooke, Josh Deblieux, Cameron Simmons, Kiondra Fisher, Jason Webb, Michael Hoerger
Palliative care (PC) is specialized medical care for people living with a serious illness. PC models have stressed pain and symptom management, communication that is patient- and family-centric and longitudinal support for families living with serious illness that is contiguous across multiple settings. Despite the benefits that PC provides from a patient, family and quality of care standpoint, several
-
Creating a culture for change: Lessons from behavioral economics and complexity science to increase serious illness conversations for patients with cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-10-15 Ramy Sedhom, Jasmine Tomita-Barber, Christopher R. Manz, Ravi B Parikh, Arjun Gupta, Qasim Hussaini, David Dougherty
Patient-centered cancer care requires communication between patients and clinicians about patients’ goals, values, and preferences. Serious illness communication improves patient and caregiver outcomes, the value and quality of cancer care, and the well-being of clinicians. Despite these benefits, there are competing factors including time, capacity, bandwidth, and resistance. Health systems and oncology
-
Early and often: Promoting early integration of pediatric palliative care for seriously ill children with cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-10-16 Sara Taub, Robert Macauley
Pediatric palliative care, despite substantial overlap with its adult counterpart, is also distinct in some ways. Serious illness and comorbidities are less common in children, for whom there is a stronger presumption toward aggressive treatment. This, along with impressive cure rates for pediatric cancer, can help explain why children typically survive for a longer period of time following initial
-
Palliative care integration for patients on phase I cancer clinical trials Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-10-16 Anna-Carson R. Uhelski, Margaret Wheless, Elizabeth J. Davis, Rajiv Agarwal
Early integration of palliative care (PC) is recommended as standard of care for patients with advanced cancer. However, challenges remain for both medical oncologists and PC specialists in knowing how to best integrate PC within the dynamic landscape of cancer therapeutics and drug development. Over the last several years in oncology, the success of immunotherapy and molecularly targeted agents has
-
Bridging the gap: Palliative care integration into survivorship care Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-10-15 Brianna Morgan, Vishal Kapadia, Lesa Crawford, Samina Martin, Joseph McCollom
As the number of cancer survivors grows, there is an increasing need for comprehensive care to address the unique physical, psychological, and social needs of this population. Palliative care (PC) integration within survivorship care offers a promising model of care, however, there is no comprehensive review of literature to guide clinical practice. This manuscript presents a scoping review of the
-
Risk factors for omental metastasis and the effect of omentectomy on survival in type 2 endometrial cancer patients Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-10-13 Varol Gülseren, İlker Çakır, Esra Canan Kelten, Aykut Özcan, Muzaffer Sancı, Ertuğrul Şen, Zübeyde Emiralioğlu Çakır, İsa Aykut Özdemir, Kemal Güngördük
To investigate the risk factors for occult omental metastasis and the effect of omentectomy on the survival of type 2 endometrial cancer (EC) patients. This study enrolled patients who were diagnosed with high-risk (grade 3, serous, clear cell, undifferentiated, carcinosarcoma, or mixed type) EC between 2000 and 2021 and underwent surgery in our center. Data from 482 patients were analyzed retrospectively
-
Innovations and Opportunities for the Integration of Palliative Care in Cancer Care Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-27 Kristina B. Newport, Jason A. Webb
Abstract not available
-
Established and new treatment roadmaps for pleural mesothelioma: opinions of the Turkish Collaborative Group Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-27 Muhammet Ali Kaplan, Mehmet Ali Nahit Şendur, Ayten Kayı Cangır, Pınar Fırat, Erdem Göker, Saadettin Kılıçkap, Başak Oyan, Ayşim Büge Öz, Feyyaz Özdemir, Gökhan Özyiğit
Pleural mesothelioma (PM) is a cancer of the pleural surface, which is aggressive and may be rapidly fatal. PM is a rare cancer worldwide, but is a relatively common disease in Turkey. Asbestos exposure is the main risk factor and the most common underlying cause of the disease. There have been significant improvements in diagnoses and treatments of many malignancies; however, there are still therapeutic
-
Peripheral Arterial Disease is Associated With Higher Rates of Hospital Encounters and Mortality in Cancer Patients: A Retrospective Study Conducted at a Tertiary Cancer Center Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-19 Yolanda Bryce, Meier Hsu, Charlie White, Adrian Gonzalez-Aguirre, Adie Friedman, Jonathan Latzman, Chaya S. Moskowitz
Cancer and peripheral arterial disease (PAD) have overlapping risk factors and common genetic predispositions. The concomitant effects of PAD and cancer on patients have not been well studied. The objective of this retrospective study is to evaluate outcomes of cancer patients with PAD. A query was made into Memorial Sloan Kettering Cancer Center's database to assess outcome of patients with and without
-
Prognostic role of the peritoneal cancer index in ovarian cancer patients who undergo cytoreductive surgery: a meta-analysis Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-14 Shu-Li Yang, Li-Hui Si, Rui-Xin Lin, Shi-Yu Gu, Jia-Hui Li, Jun-Ze Cui, Chu-Han Yan, Abdulkarim Mohamed Farah, Yan Jia
Advanced-stage ovarian cancer is usually associated with peritoneal carcinomatosis. This study evaluates the prognostic role of the Peritoneal Cancer Index (PCI) in predicting the survival of patients with ovarian cancer. A literature search was conducted in electronic databases (Google Scholar, PubMed, Ovid, and Science Direct) and study selection was based on precise eligibility criteria. Random-effects
-
Examining the Cultural Appropriateness of Advance Care Planning Tools for Adolescents and Young Adults With Cancer: An Example of Cross-Cultural Adaptation of the Voicing My CHOiCES Tool Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-11 Holly E. Evans, Sophie Jessop, Sima Z. Bedoya, Maureen E. Lyon, Lori Wiener, Ursula M. Sansom-Daly
Advance care planning (ACP) is crucial in supporting optimal, patient-centered care for adolescents and young adults (AYAs) with life-limiting illnesses and can reduce unwanted outcomes at end-of-life. While several ACP tools and interventions have been designed for AYAs, most of these were developed in the United States of America (USA). This paper describes a study designed to adapt the AYA ACP tool
-
Innovations for the integration of palliative care for hematologic malignancies Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-06 Neha Kayastha, Alison R. Kavanaugh, Jason A. Webb, Thomas W. LeBlanc
Specialist palliative care provides additional support to facilitate living well with a serious illness, like cancer, even while pursuing disease-directed therapy. For patients with hematologic malignancies, integrated specialist palliative care improves symptom burden, mood, and quality of life, with benefits even extending to caregivers. Despite this, patients with hematologic malignancies continue
-
Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC) Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-06 Laura Fernández Madrigal, M Yeray Rodriguez Garcé, Francisco Javier Jiménez Ruiz
Hereditary breast and ovarian cancer syndrome (HBOC) is associated with other genes beyond BRCA. The performance of prophylactic bilateral mastectomy (PBM) and risk-reducing salpingo-oophorectomy (RRSO) are primary prevention measures that can be recommended depending on the type of pathogenic/likely pathogenic (P/LP) variant detected or family history. Descriptive, retrospective, and observational
-
Integrating palliative care into the evolving landscape of oncology Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-06 Harry J. Han, Carol R. Pilgrim, Mary K. Buss
Patients with cancer have many palliative care needs. Robust evidence supports the early integration of palliative care into the care of patients with advanced cancer. International organizations, such as the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), have recommended early, longitudinal integration of palliative care into oncology care throughout
-
Integrated dual training in palliative care and oncology Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-06 Kathryn DeCarli, Rachel Rodenbach, Ramy Sedhom, Jamie von Roenn, Briana Ketterer
Fellowship training in Hospice and Palliative Medicine (HPM) and Hematology/Oncology (Hem/Onc) share common themes and roots in the holistic care of people living with cancer. As of 2021, approximately 630 physicians in the United States were board-certified in both HPM and Hem/Onc. There is increasing demand for an integrated fellowship pathway, and the inaugural integrated fellowship Match took place
-
Practical considerations for prognostic communication in pediatric cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-05 Brittany Cowfer, Tammy I. Kang, Matthew T. McEvoy
High-quality communication is essential for the optimal care of children with cancer and their families. There are opportunities for pediatric oncologists to engage in clear and compassionate prognostic communication across the disease trajectory including at the time of diagnosis, disease recurrence or progression, and end of life. Contrary to previously held beliefs, prognostic disclosure supports
-
The prognostic value of FIGO staging defined by combining MRI and [18F]FDG PET/CT in patients with locally advanced cervical cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-09-05 Stefano Raffa, Francesco Lanfranchi, Camilla Satragno, Flavio Giannelli, Michela Marcenaro, Angela Coco, Sofia Elizabeth Cena, Luca Sofia, Cecilia Marini, Serafina Mammoliti, Alessia Levaggi, Alberto Stefano Tagliafico, Gianmario Sambuceti, Salvina Barra, Silvia Morbelli, Liliana Belgioia, Matteo Bauckneht
The last version of the FIGO classification recommended imaging tools to complete the clinical assessment of patients with cervical cancer. However, the preferable imaging approach is still unclear. We aimed to explore the prognostic power of Magnetic Resonance Imaging (MRI), contrast-enhanced Computed Tomography (ceCT), and [18F]-Fluorodeoxyglucose Positron Emission Tomography ([18F]FDG-PET)/CT in
-
-
-
-
Gynecologic and Breast Cancers: What's New in Chemoresistance and Chemosensitivity Tests? Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-07-08 Júlia Caroline Marcolin, Martina Lichtenfels, Camila Alves da Silva, Caroline Brunetto de Farias
Gynecological and breast cancers affect women's health worldwide. Although chemotherapy is one of the principal treatments for cancer, it also has limitations owing to toxicity and tumor resistance to the drugs used. Thus, individualized treatment based on personal tumor characteristics is essential for improving therapeutic outcomes and patient survival. Chemoresistance and chemosensitivity tests
-
Advances in high-risk localized prostate cancer: Staging and management Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-07-04 Yeison Reina, Catalina Villaquirán, Herney Andrés García-Perdomo
Nearly 15% of individuals with localized prostate cancer are identified as high risk for recurrence and progression of the disease, which is why the correct staging is vital for the definition of correct treatment—also developing novel therapeutic strategies to find a balance between getting better outcomes without sacrificing the quality of life (QoL). In this narrative review, we introduced the current
-
Repurposing Metformin in hematologic tumor: State of art Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-06-20 Min Hu, Yan Chen, Tao Ma, Li Jing
Metformin is an ancient drug for the treatment of type 2 diabetes, and many studies now suggested that metformin can be used as an adjuvant drug in the treatment of many types of tumors. The mechanism of action of metformin for tumor treatment mainly involves: 1. activation of AMPK signaling pathway 2. inhibition of DNA damage repair in tumor cells 3. downregulation of IGF-1 expression 4. inhibition
-
-
Imaging of colon and rectal cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-06-08 Sonia Lee, Venkateswar R. Surabhi, Zahra Kassam, Kevin J. Chang, Harmeet Kaur
Colon and rectal cancer imaging has traditionally been performed to assess for distant disease (typically lung and liver metastases) and to assess the resectability of the primary tumor. With technological and scientific advances in imaging and the evolution of treatment options, the role of imaging has expanded. Radiologists are now expected to provide a precise description of primary tumor invasion
-
Imaging of breast cancer–beyond the basics Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-06-07 Michelle Zhang, Benoit Mesurolle, Melanie Theriault, Sarkis Meterissian, Elizabeth A. Morris
Imaging of breast cancer is the backbone of breast cancer screening, diagnosis, preoperative/treatment assessment and follow-up. The main modalities are mammography, ultrasound and magnetic resonance imaging, each with its own advantages and disadvantages. New emerging technologies have also enabled each modality to improve on their weaknesses. Imaging-guided biopsies have allowed for accurate diagnosis
-
Update on the Role of Imaging in Staging of Common Pediatric Abdominal Tumors Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-06-07 Sujit Kumar Jha, Colin Brown, Lisa Kang, Eric S. Diaz, Kriti Gwal, Elysia Alvarez, Erin G. Brown, Rebecca Stein-Wexler
Neuroblastoma, Wilms tumor, and hepatoblastoma are the most common pediatric abdominal malignancies. Management of these diseases is a multidisciplinary process that continues to evolve based on the results of international collaborative trials and advances in understanding of tumor biology. Each of these tumors has unique characteristics and behavior which are reflected in their respective staging
-
Imaging of lung cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-06-04 Mohammad H. Madani, Jonathan W. Riess, Lisa M. Brown, David T. Cooke, H. Henry Guo
Lung cancer is the leading cause of cancer-related mortality globally. Imaging is essential in the screening, diagnosis, staging, response assessment, and surveillance of patients with lung cancer. Subtypes of lung cancer can have distinguishing imaging appearances. The most frequently used imaging modalities include chest radiography, computed tomography, magnetic resonance imaging, and positron emission
-
Imaging cancer in neuroradiology Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-06-04 Osama Raslan, Arzu Ozturk, Kader Karli Oguz, Orwa Aboud, Vladimir Ivanovic, Reza Assadsangabi, Lotfi Hacein-Bey
Neuroimaging plays a pivotal role in the diagnosis, management, and prognostication of brain tumors. Recently, the World Health Organization (WHO) published the fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS5), which places greater emphasis on tumor genetics and molecular markers to complement the existing histological and immunohistochemical approaches. Recent
-
Imaging of Hepatobiliary Cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-06-04 Benjamin W. Carney, Michael C. Larson, Michael T. Corwin, Ramit Lamba
The liver and biliary tree are common sites of primary and secondary malignancies. MRI followed by CT is the mainstay for the imaging characterization of these malignancies with the dynamically acquired contrast enhanced phases being the most important for diagnosis. The liver imaging reporting and data system classification provides a useful framework for reporting lesions in patents with underlying
-
Literature review: imaging in prostate cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-06-04 Clemens Mingels, Laura I. Loebelenz, Adrian T. Huber, Ian Alberts, Axel Rominger, Ali Afshar-Oromieh, Verena C. Obmann
Imaging plays an increasingly important role in the detection and characterization of prostate cancer (PC). This review summarizes the key conventional and advanced imaging modalities including multiparametric magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging and tries to instruct clinicians in finding the best image modality depending on the patient`s PC-stage. We aim
-
Selinexor in patients with advanced and recurrent endometrial cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-05-30 Giorgio Bogani, Bradley J Monk, Robert L Coleman, Ignace Vergote, Ana Oakin, Isabelle Ray-Coquard, Andrea Mariani, Giovanni Scambia, Francesco Raspagliesi, Bruno Bolognese
Selinexor is an oral inhibitor of the nuclear export protein called Exportin 1 (XPO1) with demonstrated antitumor activity in hematological and solid tumors. Selinexor, blocking XPO1, induces nuclear localization of tumor suppressor proteins (including p53, p73, BRCA1, and pRB), leading to the selective induction of apoptosis, and inhibition of DNA damage repair proteins. XPO1 overexpression is common
-
Risk nomogram for assessing renal recovery in patients with newly diagnosed multiple myeloma-related renal impairment Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-05-23 Shaobo Li, Min Zhang, Jin Liu, Shaojun Liu, Chen Zhu, Da Shang, Yi Guan, Qian Wang
To determine risk factors affecting renal recovery in newly diagnosed multiple myeloma (NDMM) patients with renal impairment (RI) and establish a risk nomogram. This multi-center, retrospective cohort study included 187 NDMM patients with RI, 127 of whom were admitted to Huashan Hospital and assigned to the training cohort and 60 were admitted to Changzheng Hospital and assigned to the external validation
-
Is Hypoglycemia Secondary to Metastatic Retroperitoneal Sarcoma -A Therapeutic Challenge? Case Report and Review of Literature Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-05-14 Rishi P. Nair, Atul Kumar Gupta, Puneet Pareek, Bharti Devnani, Sandeep Kumar Bairwa, Pawan K Garg, Divya Aggarwal, Smily Sharma, Tushar Mittal
Most soft tissue sarcomas afflict the extremities; however, the retro peritoneum can also be affected rarely. Retroperitoneal sarcomas are relatively asymptomatic. Although tumor-induced hypoglycemia is rare in tumors other than insulinomas, extrapancreatic tumors are a subset that displays this phenomenon. The occurrence of hypo-insulinemic hypoglycemia with low GH and IGF-1 should prompt consideration
-
Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2 Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-05-10 Vinh Dao, Gregory Heestand
The addition of antiepidermal growth factor receptor (EGFR) monoclonal antibodies, cetuximab or panitumumab, to conventional chemotherapy has improved clinical outcomes for rat sarcoma virus (RAS) wild-type advanced colorectal cancer patients, however, durable responses and 5-year overall survival rates remain limited. BRAF V600E somatic mutation and human epidermal growth factor receptor (HER2) a
-
Bone health in breast cancer Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-05-05 Praful Pandey, Aparna Sharma, Ajay Gogia
Early breast cancer is among the most common cancers worldwide. Recent advances continue to improve outcomes and increase long-term survivorship. However, therapeutic modalities are deleterious for patients' bone health. While antiresorptive therapy may partially negate this, consequent reduction in rates of fragility fractures remains unproven. Selective prescription of bisphosphonates or denosumab
-
Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-04-13 Asia N. Matthew-Onabanjo, Gabrielle Nortey, Richard S. Matulewicz, Ramsankar Basak, Donna A. Culton, Kimberly N. Weaver, Kristalyn K. Gallagher, Hung-Jui Tan, Tracy L. Rose, Matthew Milowsky, Marc A. Bjurlin
To determine the distribution of race and ethnicity among genitourinary oncology trial participants leading to FDA approval of novel molecular entities/biologics. Secondarily, we evaluated whether the proportion of Black participants in clinical trials increased over time. We quired the FDA Center for Drug Evaluation and Research Drug Trials Snapshot (DTS) between 2015 and 2020 for urologic oncology
-
Comprehensive Pan-Cancer Analysis of MTF2 Effects on Human Tumors Curr. Probl. Cancer (IF 2.6) Pub Date : 2023-03-30 Cui Tang, Ye Lv, Kuihu Ding, Yu Cao, Zemei Ma, Lina Yang, Qiqi Zhang, Haiyang Zhou, Yu Wang, Zhongtao Liu, Xiangmei Cao
Understanding oncogenic processes and underlying mechanisms to advance research into human tumors is critical for effective treatment. Studies have shown that Metal regulatory transcription factor 2(MTF2) drives malignant progression in liver cancer and glioma. However, no systematic pan-cancer analysis of MTF2 has been performed. Here, we use University of California Santa Cruz, Cancer Genome Atlas